Wechselwirkungen · Lysodren
Lysodren 500 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-112484 · Präparat HOS-093689
Substances metabolised through cytochrome P450: Mitotane has been shown to have an inductive effect on cytochrome P450 enzymes. Therefore, the plasma concentrations of the substances metabolised via cytochrome P450 may be modified. In the absence of information on the specific P450 isoenzymes involved, caution should be taken when co-prescribing active substances metabolised by this route such as, among others, anticonvulsants, rifabutin, rifampicin, griseofulvin and St. John’s wort (Hypericum perforatum). Particularly, mitotane has been shown to have an inductive effect on cytochrome 3A4. Therefore, the plasma concentrations of the substances metabolised via cytochrome 3A4 may be modified. Caution should be taken when co-prescribing active substances metabolised by this pathway such as, among others, sunitinib, etoposide and midazolam and dose should be adjusted as appropriate when coadministered with mitotane.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) etoposide (HOS-086021) sunitinib (HOS-109453) griseofulvin (HOS-091156) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-11T11:11:00Z · SHA-256 8857f8543d9dfcf9df89b956cb88735a9c924712c239c2879d16e7b6e36c86ba · Passage 33ffffa577eb2424a7b8528ae3d95c1068738efbcf5b41830673b01453bc3bf5 · Zeichen 546–1471 im Abschnitt